Quick answer: The ROI of neurology prior authorization automation software comes from three sources: reclaimed staff hours (neurology runs well above the 13 hours per physician per week the average practice spends on PA), lower denial rates, and recovered revenue on high-cost drug and procedure authorizations that currently expire or get miscoded. For a specialty practice with real PA volume, automation typically pays back within months on labor savings alone, before counting prevented denials. The return scales with volume, so high-volume neurology practices see it fastest.
The ROI formula, then the neurology specifics
The core ROI math is simple: hours saved per auth × monthly auth volume × loaded staff cost, plus the revenue you protect from fewer denials and expired authorizations. The hard part isn't the formula — it's that most practices have never priced their current state, because PA work is smeared across coordinators, medical assistants, and physicians who don't log it as a line item.
Start with the baseline. The 2024 AMA prior authorization survey found practices average 39 prior authorizations per physician per week, consuming about 13 hours of combined staff and physician time. Neurology runs higher than that average, because so much of the work — advanced imaging, EMG, Botox, infusions, and high-cost drugs — falls into the auth-required bucket.
To build your own number, time a sample of auths. In specialty workflows, the cumulative touch time per manual auth — data gathering, portal entry, repeated status checks — commonly runs 20–45 minutes. Use fully loaded staff cost (salary plus benefits and overhead), not base wage, or you'll understate the baseline by a third.
The three components of return
Neurology PA automation pays through three channels, and a credible business case treats each differently.
Reclaimed labor is the defensible floor. Automation removes data gathering, submission, and status-chasing from the routine majority of auths; staff keep the exceptions. This is nearly certain and easy to measure, so build your payback case on it alone and treat everything else as upside.
Denial prevention is the second channel. Auth-related denials — missing auth, expired auth, mismatched codes — are among the most preventable, and in neurology they cluster on Botox windows, infusion coding, and step-therapy documentation for drugs. Model this conservatively, assuming automation prevents a third to half of your auth-related denials.
Throughput is the largest and least certain channel. An MRI or infusion auth that clears in two days instead of nine is a procedure that happens a week sooner — and in neurology, those procedures are the high-revenue events. Faster turnaround also reduces patient leakage to practices with shorter waits. Track this after go-live rather than promising it up front.
A worked example you can rebuild
Take a six-neurologist specialty practice. At the AMA-measured average of roughly 39 auths per physician per week, that's about 230 auths a week, or roughly 1,000 a month — and in neurology the real number often runs higher given the procedure mix.
Suppose native electronic channels handle 35% cleanly, leaving about 650 manual auths a month. At a conservative 25 minutes of cumulative touch time each, that's around 270 staff-hours a month. At a loaded $30/hour, that's roughly $8,000 a month, or about $96,000 a year, spent on portals, faxes, and status calls.
Apply automation with an 80% touchless rate on the manual volume, and roughly 520 auths process without staff touches; the remaining 130 exceptions get a short, informed review. Monthly staff time drops to around 60–70 hours, recovering on the order of $6,000 a month — about $72,000 a year — in labor capacity. Hold that against the software cost at your volume; for most practices with this kind of volume, the labor line alone clears it several times over.
What's the payback timeline?
Practices with meaningful volume typically reach payback within two to three quarters on labor savings alone, with denial and throughput gains following over subsequent billing cycles. Two modeling disciplines keep that credible.
First, model the touchless rate at 75–85%, never 100%. Real neurology volume includes peer-to-peer reviews and judgment calls that should route to humans, and a model assuming total automation collapses the first time a partner asks a hard question.
Second, model year one on ten months, not twelve. The first quarter runs below steady state while the system learns your payer mix and your team builds trust — the 2024 CAQH Index prices a manual prior authorization at roughly $11 versus about half that electronic, but that gap only materializes once the system is tuned to your actual payers. Account for the tuning quarter and your projection survives scrutiny.
The revenue neurology practices recover
The labor math undersells the return because it ignores revenue a manual process quietly loses — and in neurology, those losses are specific and recoverable.
Botox authorizations expire when no one tracks the window, turning a covered injection into a write-off. Infusion claims get denied for missing NDC or J-code detail. High-cost drug auths — CGRP biologics at $6,000 to $8,000 a year, MS therapies — get denied on first pass when step-therapy documentation is incomplete. Each of these is preventable revenue that a fully staffed manual process still loses, because people get pulled onto other tasks and authorizations slip.
This is where a platform like Honey Health shows up in the ROI. Its Prior Authorization agent tracks auth windows and assembles the drug and procedure documentation automatically, and runs alongside its eligibility and denial management agents — so the recovered revenue isn't a one-time cleanup but a structural change in how much leaks out each month.
What to measure before and after
Lock your baseline before launch, then track five numbers quarterly so the ROI is provable, not assumed.
- Touchless rate — share of auths completed with zero staff touches; should climb toward the modeled 75–85% through the tuning quarter.
- Staff hours on PA — re-run your time sample at 90 days to validate the labor line your payback rests on.
- Auth turnaround time — order to determination, median and worst decile, by payer; the throughput lever lives here.
- Auth-related denial rate — denials coded to missing or invalid auth as a share of claims; should trend toward zero.
- Cost per auth — total spend (software plus exception labor) divided by volume, against the manual baseline; the single number a CFO can track on one line.
Review at 30, 60, and 90 days with the vendor accountable for the touchless-rate ramp. Practices that treat the first quarter as a shared tuning project consistently hit the modeled numbers; those that treat go-live as done usually leave a third of the return unclaimed.
Frequently asked questions
What's the ROI of neurology prior authorization automation software?
The ROI comes from reclaimed staff hours (neurology runs above the 13 hours per physician per week the average practice spends on PA), lower denial rates, and recovered revenue on high-cost drug and procedure authorizations. For practices with real volume, automation typically pays back within months on labor savings alone, with denial and throughput gains following.
How do you calculate prior authorization automation ROI?
Multiply hours saved per auth by monthly auth volume by loaded staff cost — that's the labor floor. Then add conservatively modeled denial prevention and track throughput gains after go-live. Time a sample of your own auths for the per-auth number, and use fully loaded staff cost rather than base wage.
How quickly does it pay for itself?
Practices with meaningful PA volume typically reach payback within two to three quarters on labor savings alone. Model year-one savings on about ten months of steady-state performance to account for the tuning quarter, when the system runs below its eventual touchless rate while learning your payer mix.
Does ROI depend on practice size?
Yes — the return scales with PA volume. High-volume neurology practices see payback fastest because the labor and denial savings compound across more auths. Lower-volume practices still benefit from fewer expired Botox authorizations and cleaner drug approvals, but should model the return against their actual monthly auth count.
What revenue does automation recover beyond labor savings?
It recovers revenue lost to expired Botox authorizations, miscoded infusions, and denied high-cost drug auths — losses a manual process incurs no matter how well-staffed, because authorizations slip when people get busy. Tracking auth windows and assembling drug documentation automatically turns those recurring write-offs into captured revenue.
What should we measure to prove the ROI?
Track five metrics against a pre-launch baseline: touchless rate, staff hours on PA, auth turnaround time, auth-related denial rate, and cost per auth. Review them at 30, 60, and 90 days with the vendor accountable for the touchless-rate ramp, so the return is demonstrated rather than assumed.
